HER2 - A discussion of testing approaches in the USA

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Thor, A ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Doxorubicin; HER2; Herceptin; Prediction; Prognosis; Tamoxifen; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR CLONING; ONCOGENE NEU; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; UNITED STATES;

EID: 0034879199     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S101     Document Type: Article

References (22)

1. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
2. HER2 as a prognostic and predictive marker for breast cancer
3. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
4. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
5. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer
6. Assessment of HER2 status by IHC, PCR and FISH to predict outcome following adjuvant doxorubicin therapy: The CALGB experience
7. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
8. HER-2/neu amplification predicts poor survival in node-positive breast cancer
9. Elevated serum c-erb-B-2 antigen levels and decreased response to hormone therapy of breast cancer
10. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
11. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
12. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
13. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
14. Lack of interaction of tamoxifen use and ErbB-2/HER-2/neu expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer
15. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in breast cancer
16. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
17. Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
18. Cross-regulation of erbB2 oncoprotein and estrogen receptor by estrogen and the erbB2 ligands (gp30/p75)
19. Prognostic factors in breast cancer
20. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational III trial
21. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
22. The basic biology of HER2